- Home
- ATAI vs IART Comparison
ATAI vs IART Comparison
Compare ATAI & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | IART |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ATAI | IART |
|---|---|---|
| Price | $4.03 | $12.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $13.86 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 4.1M | 650.7K |
| Earning Date | 11-12-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,018,000.00 | ★ $1,642,966,000.00 |
| Revenue This Year | $962.66 | $3.26 |
| Revenue Next Year | N/A | $2.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | 4.99 |
| 52 Week Low | $1.15 | $10.87 |
| 52 Week High | $6.75 | $27.13 |
Technical Indicators
Market Signals| Indicator | ATAI | IART |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 46.01 |
| Support Level | $3.50 | $11.76 |
| Resistance Level | $3.85 | $13.53 |
| Average True Range (ATR) | 0.23 | 0.70 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 80.43 | 26.06 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.